Answers are grounded in this paper and cite their sources.
Retrospective cohort study finds adding venetoclax to hypomethylating agents increases response rates without improving survival in advanced myeloproliferative neoplasms, highlighting clinical...
Patients with accelerated-phase/blast-phase myeloproliferative neoplasms (AP/BP-MPN) experience poor clinical outcomes. A multicenter, retrospective cohort study was conducted to assess outcomes of patients with AP/BP-MPN treated with hypomethylating agent (HMA) regimens. Of 188 patients included, 94 patients received HMA +/- JAK inhibitor and 56 patients received HMA + venetoclax (HMA+ven) +/- JAK inhibitor. The primary endpoint of overall survival (OS) was 9.2 months in both groups (log-rank p = 0.569). The rates of CR/CRi and CR/CRi/MLFS were higher with HMA+ven (36% vs. 11%, p = 0.0002 and 52% vs. 16%, p < 0.0001), but the rate of allogeneic hematopoietic cell transplant (alloHCT) was not different (HMA vs. HMA+ven, 14% vs. 18%, p = 0.51). Multivariate cox regression identified age and receipt of an alloHCT as significant predictors of survival. This large, multicenter, real-world analysis demonstrated the addition of venetoclax to HMA therapy in patients with AP/BP-MPN improved response rates but did not translate into an improvement in OS.
No takes yet. Share an insight, caveat, or question.
Ciervo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: